Source: Annals of Hematology. Unidade: FMRP
Subjects: LEUCEMIA, VITAMINA A, QUIMIOTERÁPICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANZ, Miguel A. et al. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, v. 94, n. 8, p. 1347-1356, 2015Tradução . . Disponível em: https://doi.org/10.1007/s00277-015-2393-0. Acesso em: 31 maio 2024.APA
Sanz, M. A., Montesinos, P., Kim, H. T., Ruiz-Argüelles, G. J., Undurraga, M. S., Uriarte, M. R., et al. (2015). All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Annals of Hematology, 94( 8), 1347-1356. doi:10.1007/s00277-015-2393-0NLM
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RAM, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vallenga E, Holowiecka A, González-Huerta AJ, Fernández P, De La Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies [Internet]. Annals of Hematology. 2015 ; 94( 8): 1347-1356.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s00277-015-2393-0Vancouver
Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RAM, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vallenga E, Holowiecka A, González-Huerta AJ, Fernández P, De La Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies [Internet]. Annals of Hematology. 2015 ; 94( 8): 1347-1356.[citado 2024 maio 31 ] Available from: https://doi.org/10.1007/s00277-015-2393-0
